BA
BAYRY.US Bayer AG PK
- Market cap
- USD 61.5B
- P/E
- -
- P/B
- 1.89x
- ROE
- 10.6%
- Dividend yield
- 0.21%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BAYRY.US undervalued?
Graham numberThe Graham number of Bayer AG PK cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bayer AG PK fundamental analysis
No fundamental analysis for Bayer AG PK yet.
Bayer AG PK stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bayer AG PK
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and d…
Full company profileBayer AG PK financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bayer AG PK annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 46.8B | 35.0B | 39.6B | 43.5B | 41.4B | 44.1B | 50.7B | 47.6B | 46.6B | 45.6B | 45.8B |
| Gross Profit | 26.5B | 23.6B | 22.6B | 26.1B | 22.3B | 27.3B | 30.9B | 27.9B | 25.3B | 26.8B | 26.6B |
| Operating Income | 7.04B | 5.90B | 3.91B | 5.04B | -2.94B | 6.98B | 6.26B | -150M | 3.33B | 6.14B | 5.66B |
| EBITDA | 7.82B | 7.76B | 6.26B | 8.77B | -11.5B | 6.97B | 10.4B | 4.21B | 8.81B | 1.92B | 10.9B |
| Net Income | 4.53B | 7.34B | 1.70B | 2.43B | -15.6B | 1.00B | 4.15B | -2.94B | -2.55B | -3.62B | 3.08B |
| EPS | 1.36 | 2.07 | 0.45 | 0.62 | -3.96 | 0.25 | 1.06 | -0.75 | -0.65 | -3.68 | 3.14 |
| Balance Sheet | |||||||||||
| Total Assets | 82.2B | 75.1B | 126B | 126B | 117B | 120B | 125B | 116B | 111B | 105B | 113B |
| Total Liabilities | 50.3B | 38.2B | 80.1B | 78.7B | 86.3B | 87.1B | 86.0B | 83.2B | 78.8B | 78.5B | 81.2B |
| Shareholders' Equity | 31.9B | 36.9B | 46.1B | 47.5B | 30.7B | 33.2B | 38.9B | 33.1B | 32.0B | 26.1B | 29.2B |
| Cash & Short-term Investments | 5.42B | 9.10B | 4.34B | 5.40B | 11.9B | 7.74B | 10.2B | 10.6B | 8.09B | 6.67B | 9.26B |
| Total Debt | 18.3B | 13.2B | 40.7B | 38.9B | 41.6B | 39.5B | 41.3B | 44.8B | 40.7B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 9.09B | 8.13B | 7.92B | 8.21B | 4.90B | 5.09B | 7.09B | 5.12B | 7.37B | 5.93B | -631M |
| Capital Expenditure | 2.58B | 2.37B | 2.59B | 2.65B | 2.42B | 2.61B | 2.95B | 2.75B | 2.78B | 2.49B | 2.39B |
| Free Cash Flow | 6.51B | 5.77B | 5.32B | 5.56B | 2.49B | 2.48B | 4.14B | 2.37B | 4.59B | 3.44B | -3.02B |
| Ratios | |||||||||||
| ROE | 14.2% | 19.9% | 3.7% | 5.1% | -50.7% | 3.0% | 10.7% | -8.9% | -8.0% | -13.9% | 10.6% |
| ROA | 5.5% | 9.8% | 1.3% | 1.9% | -13.3% | 0.8% | 3.3% | -2.5% | -2.3% | -3.5% | 2.7% |
| Net Profit Margin | 9.7% | 21.0% | 4.3% | 5.6% | -37.6% | 2.3% | 8.2% | -6.2% | -5.5% | -7.9% | 6.7% |
| Debt to Equity | 0.57x | 0.36x | 0.88x | 0.82x | 1.35x | 1.19x | 1.06x | 1.35x | 1.27x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bayer AG PK dividends
- Dividend yield
- 0.21%
- Forward dividend
- 0.03 USD
- Payout ratio
- -
- Ex-dividend date
- Apr 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 127M | 0.13 | - |
| 2024 | EUR 131M | 0.03 | - |
| 2023 | EUR 2.38B | 0.61 | - |
| 2022 | EUR 1.99B | 0.51 | 47.8% |
| 2021 | EUR 1.99B | 0.51 | 199.3% |
| 2020 | EUR 2.77B | 0.70 | - |
| 2019 | EUR 2.62B | 0.67 | 107.6% |
| 2018 | EUR 2.41B | 0.64 | 142.0% |
| 2017 | EUR 2.36B | 0.67 | 32.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Sep 20, 2017.
Who owns Bayer AG PK
- Insiders 0.00%
- Institutions 0.31%
- Public & others 99.69%
- Shares outstanding 3.93B
- Free float 3.93B
Bayer AG PK company profile
- Company name
- Bayer AG PK
- Ticker
- BAYRY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 87,775
- Fiscal year end
- December
- Address
- Kaiser-Wilhelm-Allee 1, Leverkusen, Germany, 51368
- Phone
- 49 214 30 1
- Website
- bayer.com
About Bayer AG PK
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. It has a commercial agreement with Neste to Jointly scale newgold winter canola for biofuels production. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Bayer AG PK management
10- Mr. William N. AndersonChairman of the Management Board & CEO · born 1966
- Mr. Stefan OelrichPresident of the Pharmaceuticals Division & Member of the Board of Management · born 1968
- Ms. Heike PrinzChief Talent Officer, Labor Director & Member of Management Board · born 1964
- Dr. Judith HartmannCFO & Member of Management Board · born 1969
- Mr. Rodrigo SantosMember of Management Board, Head of the Crop Science Division & President of Crop Science Division · born 1973
- Mr. Julio TrianaMember of Management Board & President of Consumer Health Division · born 1965
- Mr. Alex BuschermohleChief Information Officer, Head-Digital Transformation & IT-Crop Science Division
- Ms. Jana Marlen AckermannHead of the Investor Relations · born 1984
- Mr. Bill DoderoGeneral Counsel and Senior VP of Law Patents & Compliance
- Mr. Michael PreussHead of Communications, Government Relations and Corporate Brand